Recipharm   Report issue

For profit Phase 1 Phase 3
Founded: Paderno Dugnano Italy (1970)

Organization Overview

First Clinical Trial
2009
NCT01032304
First Marketed Drug
2002
potassium iodide (thyro-block)
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Edmond Pharma | RECIP | RECIPHARM | Recipharm AB

Active Ingredients

Marketed Drugs (2)

flucytosine (ancobon) (2018)

potassium iodide (thyro-block) (2002)

Drugs in Phase 3 Trials (1)

erdosteine (1 trial)

Drugs in Phase 1 Trials (1)

HPV16-E7-T512 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Oropharyngeal Neoplasms (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2